Early indication for a reduced burden of radiologically confirmed pneumonia in children following the introduction of routine vaccination against Haemophilus influenzae type b in Nha Trang, Vietnam. by Flasche, Stefan et al.
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Introduction:  Despite  the global  success  of  Hib  vaccination  in  reducing  disease  and  mortality,  uncertainty
about  the disease  burden  and  the  potential  impact  of  Hib  vaccination  in  Southeast  Asia  has  delayed  the
introduction  of vaccination  in  some  countries  in  the  region.  Hib  vaccination  was  introduced  throughout
Vietnam  in  July  2010  without  catch-up.  In an observational,  population  based  surveillance  study  we  esti-
mated  the  impact  of  routine  Hib  vaccination  on  all  cause  radiologically  conﬁrmed  childhood  pneumonia
in  Nha  Trang,  Vietnam.
Materials and  methods:  In 2007  active  hospital  based  surveillance  was  established  in  Khanh  Hoa  Gen-
eral  Hospital,  the  only  hospital  in Nha  Trang,  Khanh  Hoa  province.  Nasopharyngeal  samples  and  chest
radiographs  are  taken  routinely  from  all children  diagnosed  with  acute  respiratory  illness  on admission.
For  admissions  between  02/2007  and  03/2012  chest  radiographs  were  interpreted  for  the  presence  of
WHO primary  endpoint  pneumonia  and  nasopharyngeal  swabs  were  analysed  by  PCR for  the  presence
of  Inﬂuenza  A or B, RSV  and rhinovirus.  We  employed  Poisson  regression  to estimate  the  impact  of  Hib
vaccination  on radiologically  conﬁrmed  pneumonia  (RCP)  while  statistically  accounting  for  potential
differences  in  viral  circulation  in  the  post  vaccination  era  which  could  have  biased  the  estimate.
Results:  Of  3151  cases  admitted  during  the study  period,  166  had  RCP  and  major  viruses were  detected  in
1601. The  adjusted  annual  incidence  of RCP  in children  younger  than  5 years  declined  by  39% (12–58%)
after  introduction  of  Hib  vaccination.  This  decline  was  most  pronounced  in children  less than  2  years old,
adjusted  IRR:  0.52  (0.33–0.81),  and  no  signiﬁcant  impact  was  observed  in  the  2–4  years  old  who  were
not  eligible  for vaccination,  adjusted  IRR:  0.96  (0.52–1.72).
Discussion:  We  present  early  evidence  that  the  burden  of  Hib  associated  RCP  in  Nha  Trang  before  vaccina-
tion  was  substantial  and  that  shortly  after  introduction  to  the  routine  childhood  immunisation  scheme
vaccination  has substantially  reduced  that  burden.
© 2014  Elsevier  Ltd. All  rights  reserved.∗ Corresponding author at: LSHTM, Keppel Street, London,
K. Tel.: +44 020 88834477.
E-mail address: Stefan.Flasche@lshtm.ac.uk (S. Flasche).
ttp://dx.doi.org/10.1016/j.vaccine.2014.10.055
264-410X/© 2014 Elsevier Ltd. All rights reserved.1. IntroductionHaemophilus inﬂuenzae type b (Hib) is a leading cause
for childhood mortality and morbidity worldwide. Hib was
estimated to cause more than 8 million serious cases of ill-
ness and 350,000 deaths in children under 5 years of age in
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000 [1]. Common disease manifestations include pneumonia,
epticemia and meningitis. In 2006 the World Health Organisation
stimated that about 20% of all cause pneumonia and a sub-
tantial proportion of meningitis (varying geographically) could
otentially be prevented by Hib vaccination and hence recom-
ended the inclusion of Hib in all routine childhood immunisation
rogrammes [2].
The conjugate vaccine against Hib has proven safe and effec-
ive in reducing the burden of Hib disease in various settings
3–8]. In contrast to most other regions the burden of vaccine
reventable disease associated with Hib in Southeast Asia has
een perceived to be low [9–11]. As a result, Asian countries
ave been slow to include Hib vaccination into their routine
chedules, and China and Thailand have still not introduced the
accine [12]. An increasing body of evidence has been emerg-
ng that Hib substantially contributes to the burden of disease
n Asia [13–17] and that the incidence and mortality associ-
ted with Hib in Southeast Asia are in fact similar to levels
bserved in many other parts of the world, in particular in
he Americas [1]. This includes recent ﬁndings from Vietnam
18,19].
Non-bacteraemic episodes of Hib pneumonia are thought to
ubstantially contribute to the overall burden of Hib associated dis-
ase. Unlike bacteraemic infection, where isolation of a pathogen
rom blood provides well-established evidence of disease causality,
he causal pathogen for non-bacteraemic pneumonia is typically
nknown and no gold standard diagnostic techniques is avail-
ble [20–22]. Widespread pre-hospitalisation use of antibiotics
ithout prescription in Asian countries further limits proper
etiological identiﬁcation. The lack of gold standard diagnostic
echniques to identify the pathogen associated with an episode
f non-bacteraemic pneumonia obscures assessment of the vac-
ine preventable burden of Hib pneumonia in common study
esigns [23]. Furthermore, vaccine-unrelated changes in the epi-
emiology of other pathogens contributing to total number of
neumonia cases can distort population impact estimates. Strep-
ococcus pneumoniae and Haemophilus inﬂueanzae are the leading
auses of non-bacteraemic pneumonia supplemented by a sizeable
ontribution of respiratory viruses, including Rhinovirus, Inﬂuenza
nd respiratory syncytial virus (RSV) [24,25]. While most of the
erotypes causing pneumococcal disease show little variation over
ime in the absence of vaccination, serotypes 1 and 5 vary substan-
ially in prevalence over time for yet unknown reasons [26] and
re likely to cause a substantial amount of pneumonia despite low
arriage rates [27]. Similarly the outbreak size of winter viruses
an differ between seasons and can confound impact assessments
28].
Case control studies in various settings, including Pakistan
nd Bangladesh reported the Hib vaccine effectiveness against
ll cause radiologically conﬁrmed pneumonia (RCP) in children
o be between 20 and 60% [14,29–33], although methodological
roblems may  have led to inﬂated effectiveness estimates. A ran-
omised controlled trial amongst Indonesian children could not
etect any protective effect against this endpoint [17], despite
eporting a substantial impact on meningitis. No estimates of rate
eductions in RCP in the community with routine use of Hib vacci-
ation have been reported amongst Asian countries to date.
With the support of the GAVI Alliance, Vietnam has included
ib as part of a DTwP-Hib-Hep (Pentavalent; Quinvaxem, Berna
iotech Korea, Seoul, South Korea) into the childhood immunisa-
ion programme since July 2010 and achieved a 3 dose coverage
f 88% among children eligible for 3 doses by the end of 2010
34]. Employing data from active hospital based surveillance in Nha
rang, central Vietnam, we here present early evidence that Hib
accination in Vietnam is successfully reducing rates of all cause
neumonia in the targeted population. (2014) 6963–6970
2. Materials and methods
2.1. Design
We  conducted an observational, population-based surveillance
study of hospitalised respiratory illness in children under 5 years of
age. Cases were assessed with chest radiography and viral testing
of NP specimens. Cases with RCP were analysed in a ‘before-after’
approach (i.e. before and after Hib vaccine introduction) controlling
for secular trends in common viral causes of respiratory illness.
2.2. Surveillance
From February 2007 onwards active surveillance monitoring
hospitalised cases of acute respiratory infections (ARI) in children
has been conducted in Nha Trang, the capital of Khanh Hoa province
in central Vietnam. Details of the data collection and the study
population are described in detail elsewhere [18,35,36].
Brieﬂy: the catchment area of the surveillance study consists
of 16 of the 27 communes in Nha Trang excluding those with an
increased rate of foreign inhabitants. Children admitted to Khanh
Hoa General Hospital (KHGH) from February 1st 2007 through
March 31st 2012 with acute respiratory illness according to WHO
deﬁnitions (any case with cough and/or difﬁculty breathing), aged
between 1 month and 60 months on admission, residing in the
catchment area were enrolled to the study. On admission, after
obtaining informed consent from the parents or guardians, clinical
and epidemiological information was collected by the respec-
tive paediatrician. Nasopharyngeal swabs and blood samples were
taken by trained research nurses. Chest X-rays were taken within
24 h of admissions. In 2013 all chest X-rays were read indepen-
dently by two  designated radiologists according to WHO  standards
[37]. An expert panel reviewed discordant readings and a sam-
ple of positive readings. KHGH is the only hospital in Nha Trang,
Khanh Hoa province and the only one accessible for residents of
the catchment area. Hence for incidence calculations we assume
that all children with RCP are enrolled into the study and use the
population of the catchment area as denominator.
Viral nucleic acid was extracted from nasopharyngeal sam-
ples and four multiplex PCR assays were performed to detect
13 different respiratory viruses (inﬂuenza A and B, RSV, human
metapneumovirus (hMPV), parainﬂuenza virus (PIV) 1–4, rhi-
novirus, coronaviruses OC43 and 229E, adenovirus and bocavirus)
as described previously [36]. All of these viruses have been linked
to pneumonia in children [38].
The study was approved by the Institutional Review Board at
the National Institute of Hygiene and Epidemiology, Hanoi, Viet-
nam, and the Institutional Review Board at the Institute of Tropical
Medicine, Nagasaki University, Nagasaki, Japan.
2.3. Analysis
We  present both the crude relative risk (RR) of pneumonia
before and after the introduction of Hib vaccination and also an
adjusted RR estimate. To calculate the adjusted RR we statistically
adjust for differences in the circulation of viruses associated with
pneumonia which can present a potential confounder for the esti-
mation of Hib vaccination impact.
The crude RR ( ) for all cause pneumonia was  estimated
through a segmented Poisson regression model. The model
regresses the monthly number of cases of radiologically conﬁrmed
pneumonia (Pt) with an intercept (˛) to mark pre vaccination levels
and a factor (It∈Tp = 1∀t ∈ Tp and 0 elsewhere) to indicate the post
vaccination period (Tp); et represents the residual errors:
log(Pt) =  ˛ + It∈Tp + et
cine 32
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ence, the crude estimated impact of Hib vaccination on childhood
neumonia (1 − e ) is calculated as one minus the change in logged
verage monthly numbers of RCP before and after the introduction
f routine Hib vaccination.
In a ‘before-after’ design, secular changes in the outcome (RCP)
ttributable to other pathogens can confound the association
etween the exposure of interest (Hib vaccine) and the outcome
RCP). To address this we have calculated an adjusted RR that
djusts for viral circulation using viral ARI episodes as a proxy for
irculation. The adjusted RR for non-viral associated RCP (NVP)
as similarly estimated through a segmented Poisson regression
odel. With the same naming conventions as before the model
dditionally attributes excess cases of RCP (deemed virus asso-
iated pneumonia – VP), which includes both viral pneumonia
nd secondary bacterial pneumonia infections, to changes in the
onthly number of ARI due to inﬂuenza A, RSV, hMPV, parain-
uenza 3, rhinovirus, adenovirus and bocavirus (Nt,1–7). Less than
ne case per month on average of inﬂuenza B, parainﬂuenza virus 1,
 and 4 and corona virus respectively was reported in the pre vac-
ination period; hence those were excluded from the analysis to
imit the occurrence of statistical artefacts. Any potential negative
ssociation of viruses and pneumonia rates was  omitted; i.e. pres-
nce of viruses was assumed not to prevent pneumonia (1–7 ≥ 0).
og(Pt) =  ˛ + It∈Tp +
∑
i
(iNt,i) + et
n other words, we estimate the excess number of RCP due to
nﬂuenza A, RSV, hPMV, parainﬂuenza 3, rhinovirus, adenovirus
nd bocavirus to obtain adjusted number of RCP (RCP excluding
xcess VP) during the study period. Based on the adjusted number
f RCP, the NVP, we then calculate the impact of Hib vaccination on
VP (1 − e ) as one minus the change in logged average monthly
umbers of NVP before and after the introduction of routine Hib
accination. Because of multiplicity the impact on NVP in this model
lso corresponds to the impact of Hib vaccination on RCP adjusted
or the circulation of viruses. Hence, in the following we  refer to
1 − e ) in the adjusted analysis as the adjusted IRR for RCP.
S. pneumoniae is the dominant cause of pneumonia and hence
resents a potential confounder for impact estimates in an obser-
ational “before-after” study. Not accounting for pneumococcal
neumonia presents a potential limitation to our study. However,
o nasopharyngeal carriage of the major epidemic pneumococcal
erotypes 1 or 5 has been detected in those presenting with ARI
etween 29/01/2007 and 15/04/2008 suggesting low contribution
ig. 1. Case counts of acute respiratory illnesses in children under ﬁve years old and und
CP  and viral circulation. The 166 samples with diagnosis of radiological conﬁrmed pneum
 years. *The 1810 samples of acute respiratory illness where either inﬂuenza A, RSV, hu
etected from the nasopharynx were employed as a proxy to represent monthly intensity (2014) 6963–6970 6965
of serotypes 1 and 5 to the burden of pneumonia in Nha Trang
[27,35].
Cases with missing information on viral testing (4% of all cases)
were attributed proportionally according to the distribution of ARI
cases tested positive for inﬂuenza A, inﬂuenza B, RSV and rhi-
novirus or tested negative in the respective month. Similarly ARI
episodes where no chest radiograph was  taken (2% of all cases) were
attributed proportionally according to the proportion of radiologi-
cally conﬁrmed pneumonia in the respective month.
Two-tailed t-test and chi-square tests are used as appropriate to
determine the signiﬁcance of the change in the presence of clinical
features from the pre vaccination era to the post vaccination era.
Conﬁdence intervals presented refer to a conﬁdence level of 95%.
Statistical analysis was  performed in R 3.01 [39].
3. Results
3.1. Characteristics of the enrolled cases
A total of 3151 children less than 5 years of age hospitalised for
ARI were enrolled in the active ARI surveillance between February
2007 and March 2012 and a chest X-ray was  taken and inter-
preted in 98% of the cases (Fig. 1). 166 (5%) of the radiographs were
classiﬁed as cases of radiologically conﬁrmed pneumonia (primary
endpoint). 64 (2%) of the radiographs were found to be uninter-
pretable. The main burden of radiological pneumonia was amongst
the 0–1 year olds but shifted slightly towards older ages in the post
vaccination period (see Fig. 2A). Information on viral presence in
the nasopharynx was  available for 96% of all cases of ARI. At least
one virus was  detected in 1875 (61%) of the tested isolates (Table 1)
with inﬂuenza A, RSV and rhinovirus accounting for 1545 (82%) of
these isolates. Inﬂuenza A and RSV were more common among ARI
in the period before vaccination (see Fig. 2B) while the less common
viruses, including PIV3, hMPV and adenovirus, were more present
in the post vaccination period. This presents a potential issue of
confounding in a “before-after” analysis if not adjusted for.
Of all study participants 56% presented with fever (Table 1).
Other common symptoms included dyspnoea and increased respi-
ratory rate. The rate of antibiotic usage prior to admission did not
change signiﬁcantly in the post vaccination period. A higher propor-
tion of children who  were found positive for RCP presented with
increased respiratory rate, chest wall indrawing, stridor or fever
than of those children who were found RCP negative. Changes in
clinical features towards milder symptoms were observed in the
period after introduction of Hib vaccination which were similar in
both RCP positive and negative cases.
er two years old that were included in the study and the stratiﬁcation into data on
onia were used to estimate the impact of Hib vaccination in children younger than
man metapneumovirus, parainﬂuenza 3, rhinovirus, adenovirus or bocavirus was
 of viral circulation in children less than 5 years of age.
6966 S. Flasche et al. / Vaccine 32 (2014) 6963–6970
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s  RCP or found to carry a viral infection.
.2. Presence of RCP before and after the introduction of Hib
accination
The average annual incidence of radiologically conﬁrmed child-
ood pneumonia was 2.68 cases per 1000 population before
accination and 1.71 cases per 1000 population after vaccination
Fig. 3A). The average annual incidence of radiologically con-
rmed pneumonia, adjusted for viral circulation (NVP), in children
ounger than 5 years declined from 1.7 cases per 1000 children
efore to 1.1 cases per 1000 children after introduction of Hib vac-
ination (Table 2). This corresponds to a reduction of 39% (12–58%)
n NVT and also all cause RCP. The introduction of routine child-
ood vaccination of Hib coincided with a decrease in cases of acute
espiratory illness where RSV was detected, however, more parain-
uenza virus type 3 and more adenovirus was found (Fig. 2B and
). RSV was estimated to increase NVP incidence by 15% (2–29%)
efore and 9% (1–18%) after the start of Hib vaccination. Parain-
uenza virus type 3 and adenovirus were found to increase NVP
ncidence by 10% (0–22%) and 19% (−2% to 43%) before and 20%
−1% to 44%) and 22% (−3% to 51%) after vaccination (see Fig. 3B).
o correlation between the co-circulation of the remaining viruses
nd RCP was found in this age group.
No children older than 2 years have been eligible for vaccination
uring the study period and hence were protected by direct vaccine
ffects. We ﬁnd no signiﬁcant reduction of RCP incidence amongst
–4 year old children. However, most of the childhood pneumonia
urden was in children under the age of 2 years with an annual
CP incidence of 5.8 cases per 1000 children before vaccination
Table 2). In this age group we estimated a substantial decline of
re vaccination RCP incidence to 3.1 cases per 1000 population after
accination corresponding to a reduction of 48% (19–67%).rmed pneumonia. (B) Comparison of nasopharyngeal carriage of viruses amongst
ildhood immunisation. (C) Timeline of the number of cases of ARI either classiﬁed
4. Discussion
We  present here an early estimate of the impact of Hib vaccine
on all cause pneumonia from an observational, population based
surveillance study in children less than ﬁve years of age, account-
ing for differences in viral circulation in the pre and post vaccination
era. We  ﬁnd early evidence that within 21 months after the intro-
duction of Hib vaccination the burden of all cause pneumonia in
children less than 2 years of age in Nha Trang has already been
substantially reduced. However, only a small and not signiﬁcant
reduction in RCP in older children who have not been eligible for
routine vaccination was observed.
Few studies have assessed the effect of Hib vaccination on RCP
and even fewer in Asia. To date most studies that were conducted
in Asia reported effectiveness estimates from case-control designs
rather than population based incidence impact. Vaccine effective-
ness was estimated to be 31% (−9% to 57%) in Brazil, 55% (7–78%)
in children receiving three vaccine doses in Colombia, 21% (5–35%)
in Gambia, 22% (−7% to 43%) in Chile, 45% (18–63%) in Ukraine
and 62% (47–73%) in Pakistan [14,29–32]. All but Gambia and Chile
were case control studies. The vaccine preventable proportion of
RCP was  35% and 44% in a case control study in Bangladesh when
using community and hospital controls respectively [33]. However,
case control designs may  overestimate vaccine effectiveness if vac-
cinated and unvaccinated communities differ signiﬁcantly in their
risk of pneumonia. The only study that did not detect any impact
amongst children was  a randomised controlled trial conducted in
Indonesia, although a signiﬁcant impact on meningitis and non-
radiological pneumonia was shown in the same study [17]. Our
ﬁndings suggest that routine childhood Hib vaccination is associ-
ated with a signiﬁcant reduction in the burden of radiologically
S. Flasche et al. / Vaccine 32 (2014) 6963–6970 6967
Table  1
Demographic and clinical features of enrolled cases. The number of positives is reported along with the proportion in all cases. Where appropriate the mean and the standard
deviation is reported instead. Where information on clinical features in some reports the reduced sample size of complete reports is given.
RCP Non-RCP
Pre-vaccine period Post-vaccine period P value* Pre-vaccine period Post-vaccine period P value*
N = 126 N = 40 N = 2136 N = 785
Age <60 month
Male 67 (53%) 19 (48%) 0.53 1296 (61%) 467 (60%) 0.56
Age  <24 month 92 (73%) 24 (60%) 0.12 1554 (73%) 562 (72%) 0.53
Kindergarten attended 60 (48%) 24 (60%) 0.17 895 (42%) 321 (41%) 0.62
Clinical features
Increased respiratory rate 39 (31%) 5 (13%) 0.02 379 (18%) 70 (9%) <0.001
Chest  indrawing 13 (10%) 1 (3%) 0.19 123 (6%) 38 (5%) 0.34
Stridor 2 (2%) 0 (0%) 1 13 (1%) 10 (1%) 0.07
Body  temperature ≥38.0 ◦C 94 (75%) 18 (45%) <0.001 1336 (63%) 282 (36%) <0.001
Pre-hospital antibiotics 38 (45%) 14 (41%) 0.73 617 (42%) 342 (47%) 0.03
Days  from onset to admission 3.1 ± 2.6 3 ± 3.3 0.88 3.1 ± 2.9 2.3 ± 2.5 <0.001
WBC  count, x103ˆ 16.8 ± 8.8 16 ± 8.6 0.59 12.8 ± 6.9 13.1 ± 7.3 0.31
Any  virus 72 (61%) 25 (64%) 0.73 1287 (62%) 491 (67%) 0.01
RCP  Non-RCP
Pre-vaccine period Post-vaccine period P value* Pre-vaccine period Post-vaccine period P value*
N = 92 N = 24 N = 1554 N = 561
Age <24 month
Male 51 (55%) 14 (58%) 0.8 985 (63%) 351 (63%) 0.73
Kindergarten attended 39 (42%) 10 (42%) 0.95 470 (30%) 155 (28%) 0.25
Clinical features
Increased respiratory rate 30 (33%) 3 (13%) 0.07 287 (18%) 52 (9%) <0.001
Chest  indrawing 9 (10%) 0 (0%) 0.2 98 (6%) 29 (5%) 0.33
Stridor 2 (2%) 0 (0%) 1 10 (1%) 5 (1%) 0.55
Body  temperature ≥38.0 ◦C 69 (75%) 10 (42%) 0.002 947 (61%) 181 (32%) <0.001
Pre-hospital antibiotics 27 (44%) 9 (43%) 0.91 420 (40%) 237 (46%) 0.016
Days  from onset to admission 3.3 ± 2.8 2.6 ± 3.1 0.34 3.2 ± 3.0 2.4 ± 2.5 <0.001
WBC  count, ×103 17.2 ± 8.9 15.3 ± 8.8 0.33 13.0 ± 6.6 13.5 ± 7.8 0.2
Any  virus 60 (68%) 18 (75%) 0.52 957 (63%) 367 (66%) 0.21
RCP  Non-RCP
Pre-vaccine period Post-vaccine period P value* Pre-vaccine period Post-vaccine period P value*
N = 34 N = 16 N = 582 N = 224
Age 24–59 month
Male 16 (47%) 5 (31%) 0.37 311 (53%) 116 (52%) 0.67
Kindergarten attended 21 (62%) 14 (88%) 0.1 425 (73%) 166 (74%) 0.76
Clinical features
Increased respiratory rate 9 (26%) 2 (13%) 0.47 92 (16%) 18 (8%) 0.004
Chest  indrawing 4 (12%) 1 (6%) 1 25 (4%) 9 (4%) 0.86
Stridor 0 (0%) 0 (0%) 1 3 (1%) 5 (2%) 0.042
Body  temperature ≥38.0 ◦C 25 (74%) 8 (50%) 0.1 389 (67%) 101 (45%) <0.001
Pre-hospital antibiotics 11 (46%) 5 (38%) 0.74 197 (50%) 105 (51%) 0.89
Days  from onset to admission 2.5 ± 2.2 3.5 ± 3.5 0.27 2.8 ± 2.6 2.2 ± 2.3 0.002
WBC  count, ×103 15.8 ± 8.3 17.0 ± 8.4 0.61 12.2 ± 7.6 12.2 ± 6.0 1
Any  virus 12 (40%) 7 (44%) 0.81 330 (58%) 151 (68%) 0.008
* Chi-square tests for categorical variables and t-tests for numerical variables as appropriate.
Deﬁnitions:  Chest indrawing: child’s chest wall moves in or retracts during inhalation; increased respiratory rate for children younger than 2 month is deﬁned as at least
60  breaths per minute, for children 2–12 month olds at least 50 breaths per minute, and for children older than 12 months at least 40 breaths per minute; antibiotic usage
within  14 days prior to admission is recognised here as possibly affecting the susceptibility to bacterial pneumonia.
Table 2
Annual incidence per 1000 population in the pre and post Hib vaccination era and the corresponding incidence risk ratio. Both results adjusted and not adjusted for viral
circulation are shown.
Incidence before vaccinationa Incidence after vaccinationa Incidence risk ratio
<5y
Adjusted 1.71 (1.21–2.39) 1.05 (0.66–1.63) 0.61 (0.42–0.88)
Crude  2.68 (2.24–3.17) 1.71 (1.24–2.28) 0.64 (0.44–0.90)
<2y
Adjusted 3.01 (1.98–4.46) 1.57 (0.89–2.67) 0.52 (0.33–0.81)
Crude  5.84 (4.73–7.10) 3.06 (2.01–4.41) 0.52 (0.33–0.80)
2-4y
Adjusted 0.86 (0.49–1.45) 0.82 (0.43–1.47) 0.96 (0.52–1.72)
Crude  1.09 (0.76–1.49) 1.01 (0.60–1.59) 0.93 (0.51–1.65)
a Note that the unadjusted incidence refers to all cause RCP while the adjusted incidence refers to non-virus associated RCP. Also the mean incidence presented here is
assuming Poisson distributed count data and hence is lower than previously reported estimates which assumed normal distributed counts [18].
6968 S. Flasche et al. / Vaccine 32 (2014) 6963–6970
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djusted model including its 95% conﬁdence intervals (grey shaded area). (B) The co
ases.  In both ﬁgures the vertical grey bar represents the introduction of Hib vaccin
onﬁrmed pneumonia in young children in Vietnam. This supports
oth the presence of a high burden of Hib pneumonia in Vietnam
n the absence of vaccination and a high impact of routine vaccina-
ion with DTwP-Hib-Hep. The lack of a measurable impact of Hib
accination in children between 2 and 4 years of age and too old
o be vaccinated may  suggest that herd protection has not been
stablished yet and in subsequent years could further beneﬁt the
nvaccinated [40].
Only 5% of all children hospitalised with acute respiratory symp-
oms were classiﬁed as primary endpoint pneumonia according to
HO deﬁnitions in our study. This is substantially less than the
espective fraction of RCP cases among hospitalised children in
ther studies [14,31,41]. This reﬂects a low threshold for admis-
ion for children with respiratory infections in this part of Vietnam.
ree of charge health insurance for all children under the age of 6
ears, good accessibility of the hospital within the study area and a
 child only policy in Vietnam are likely to have contributed to the
ow threshold for admission, and therefore inclusion in our study
nd hence a low proportion of RCP cases among them.
While RCP incidence in Vietnam is low in comparison with other
iddle income settings [18] we estimate that annually 1.44 cases
f RCP per 1000 population in children less than 2 years of age
ave already been prevented by the yet immature Hib vaccination
rogramme. Few other estimates are available for the vaccine pre-
entable burden of severe, non-bacteraemic pneumonia associated
ith Hib because of the lack of sensitivity and speciﬁcity of diagnos-
ics. A randomised trial conducted in Chile has reported the burden
f vaccine preventable RCP due to Hib at 1.1 per 1000 children of
ge 4–23 month [32]. A review on the global burden of Hib in 2000
stimated that in Southeast Asia the vaccine preventable burden of
ib meningitis and clinical pneumonia was 0.27 and 17.9 cases per
000 children under 5 years of age respectively [1].
In several instances we chose assumptions in our estimates that
ay  have led to an under estimation of the true impact of Hib vac-
ination on RCP (i.e. conservative assumptions). (A) In the absence
f a catch up campaign a large proportion of individuals younger
han 2 years of age have not been eligible for vaccination in the 21
onths after vaccine introduction that we consider here. Hence our
arly estimate the impact of routine Hib vaccination is may  be an
nderestimate of the full impact of Hib vaccination, although most
ib pneumonia is likely to occur in the ﬁrst year. With an increas-
ng duration of follow up a transition period can be included in the
egression model to account for the initial period of low vaccination
ligibility in the considered age groups and provide an estimate of
he full impact of Hib vaccination. (B) We  assume that a reduction
f virus circulation among children presenting with acute respira-
ory symptoms is not associated with Hib vaccination. However, the
bserved decline could partly be due to a reduction in co-infections
f viruses and Hib. In this case the crude estimate would be a more cases of pneumonia in under 5 year olds (line with data points) and the ﬁt of the
tion of the estimated regression parameters to the modelled logged number of RCP
to Vietnam.
accurate estimate of the actual impact of Hib vaccination on RCP.
(C) The decrease in severity of symptoms of children diagnosed
with RCP at Khanh Hoa General Hospital in the post vaccination
period could suggest an increase in health care seeking of chil-
dren with milder symptoms. This could have led to an increase
in the number of acute respiratory cases and RCPs reported over
time, and in particular to an overrepresentation of ARI in the post
vaccination era. On the other hand, it could reﬂect the rapid disap-
pearance of severe childhood pneumonia associated with improved
care seeking and overall socioeconomic development. When tested
in a linear regression model we found no evidence for a signiﬁ-
cant decrease in RCP incidence during the pre vaccination era. (D)
We do not account for possible changes in pneumococcal pneumo-
nia, in particular due to volatile serotypes 1 and 5. In a subset of
the pre vaccination period no serotype 1 or 5 carriage in children
presenting with ARI was detected suggesting a low contribution
of those types to pneumonia during this period [35] so any bias
would likely underestimate the impact of Hib vaccination. There
is no evidence available that allowed assessment of the circulation
of pneumococcal serotypes and hence potential biases during the
study period. However, a previous study did not ﬁnd evidence of
serotype 1 and 5 causing invasive pneumococcal diseases in Viet-
nam during the decade ending in 2002 [42] so their impact may  be
generally low in this setting and hence unlikely to greatly impact
on our estimates. However in settings where those serotypes are
more dominant, e.g. in Africa, this adjustment can be essential.
Among the non-RCP ARI cases antibiotic usage during the 2
weeks prior to hospital admission has increased by about 12% in the
post vaccination era and hence potentially reduced the likelihood of
developing RCP. Also the likelihood for the development of RCP on
admission has potentially been reduced in the post vaccination era
as the time from illness onset to hospitalisation decreased. Both,
changes in antibiotic usage and timeliness of health care seeking
could have led to an overestimation of the impact of Hib vaccination
in our analysis. However, antibiotic usage and timeliness of health
care seeking was similar between RCP cases and ARI cases with-
out RCP suggesting that those factors had only modest impact on
the development of RCP for a case admitted with acute respiratory
symptoms in the study population. Furthermore, after the introduc-
tion of Hib vaccination we  ﬁnd little or no change in RCP incidence
in 2–4 year old children, who were not eligible for vaccination in
the study period tentatively suggesting that the observed impact
among less than 2 year old children is vaccine speciﬁc and that
potential changes in treatment and healthcare seeking behaviour
in the population had little impact on RCP incidence.
The regression analysis includes several assumptions and
limitations. Negative associations of viral circulation and RCP
were not permitted. If virus associated illnesses were extensively
treated with antibiotics, the circulation of such viruses could have
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 preventive rather than a supportive effect on bacterial pneu-
onia. Nevertheless, inﬂuenza, RSV and rhinovirus are generally
ound to increase the risk of pneumonia [43–47]. However, we
ould not ﬁnd seasonally increased circulation of inﬂuenza A or
 to be associated with a concurrent increase in radiologically
onﬁrmed pneumonia (Fig. 2C). Furthermore the limited number
f cases only allowed for monthly resolution of the data. Hence,
ossible lags between viral infection and associated secondary
acterial pneumonia were not accounted for. Moreover Inﬂuenza A
ubtypes were not differentiated in the analysis. If these subtypes
ere associated with signiﬁcantly different risk for pneumonia
his could have masked the true contribution of the subtypes on
P. Also the adequacy of chest radiographs as gold standard for
neumonia diagnosis may  be questioned [48], however, we use of
ultiple independent readers to minimise non-speciﬁcity.
We further tested the sensitivity of our results to the choice of
odel. Instead of limiting the viruses in the model to those with
ufﬁciently high detection frequency we included all viruses in the
odel. The corresponding incidence risk ratio in children less than
wo years of age was estimated at 0.53 (0.33–0.82). Although no
igniﬁcant trend was found prior to vaccination we estimated the
ffects of Hib vaccination in children less than 2 years of age via
he crude analysis but adjusting for a linear trend in both the pre
nd post vaccination era. The corresponding incidence risk ratio
as estimated at 0.43 (0.22–0.85). Furthermore we  excluded the
eriod from February 2007 to February 2008 from the analysis to
ssess whether this period of increased RCP incidence could have
onfounded our analysis. When excluding this period the estimated
ncidence risk ratio in children less than two  years old was  0.51
0.32–0.81). Hence the substantial impact of Hib vaccination on
ll cause primary endpoint pneumonia in Nha Trang is relatively
obust to model choice.
. Conclusions
This study provides evidence that less than 2 years after intro-
uction of routine vaccination against Hib in Vietnam a substantial
mpact on all cause RCP in children less than 5 years old has been
bserved. This is driven by children under 2 years of age, of whom
ost have been vaccinated. Although an underlying secular trend
annot be ruled out, this study adds to the body of evidence that
he preventable burden of Hib pneumonia in Asian countries may
e substantial. More post vaccination surveillance data is needed
o provide more robust estimates and to detect evidence for herd
rotection.
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